Pharma companies overcharged consumers by ₹10,000 crore despite price controls: data

Pharmaceutical companies have allegedly overcharged consumers by more than ₹10,000 crore despite price caps imposed on essential medicines, according to data from the National Pharmaceutical Pricing Authority (NPPA).

The regulator has raised recovery demands under Drug Price Control Orders for charging prices higher than approved limits.

As of September 2025, NPPA has raised total demands of ₹10,013.3 crore, of which ₹8,526.1 crore remains unrecovered.

A significant portion of the pending amount—around ₹5,938.7 crore—is currently under litigation or dispute, with companies challenging NPPA’s recovery orders in courts.

Recovery has remained slow, with only ₹1,487.1 crore collected so far. NPPA data also shows that recovery in the first six months of 2025–26 increased compared to the previous year, though legal challenges continue to delay enforcement against several major pharmaceutical firms.

Recoveries raised (including interest) during FY 2025–26

Swiss Garnier Genexiaa Sciences Pvt Ltd – Nifutin 100 mg tablets: ₹12.81 crore

Torrent Pharmaceuticals – Regestrone CR 10 tablets: ₹6.58 crore

USV Ltd – Clopidogrel 75 mg tablets: ₹4.54 crore

Unichem Laboratories Ltd – Trilostar 6.25 tablets: ₹3.32 crore

Lupin Ltd – Telista 20 tablets: ₹2.37 crore

(Recoveries made up to September 2025 include ₹3.03 crore from Torrent Pharmaceuticals, ₹1.86 crore from USV Ltd, ₹1.35 crore from Unichem Laboratories Ltd, and ₹87.86 lakh from Lupin Ltd)

Related Posts

Over 9,000 deaths due to respiratory diseases in Delhi

New Delhi:  The national capital recorded 9,211 deaths due to respiratory diseases in 2024, up from 8,801 in 2023, continuing an upward trend seen over the past few years, according…

Nebuliser, inhaler demand for children jumps by up to 60 pc in Delhi winters: Survey

New Delhi:  The demand for nebulisers, inhalers and respiratory medicines for children has surged sharply in Delhi during winter months, with chemists reporting spikes of up to 60 per cent…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Over 9,000 deaths due to respiratory diseases in Delhi

Over 9,000 deaths due to respiratory diseases in Delhi

Nebuliser, inhaler demand for children jumps by up to 60 pc in Delhi winters: Survey

Nebuliser, inhaler demand for children jumps by up to 60 pc in Delhi winters: Survey

Pharma company, its employees convicted for ‘illegal diversion” of meth precursor abroad

Pharma company, its employees convicted for ‘illegal diversion” of meth precursor abroad

Ayurveda practitioner fined by ISM Council for violation of professional ethics

Ayurveda practitioner fined by ISM Council for violation of professional ethics

Administering rabies vaccine at the wrong site can be fatal: Shoulders or thighs only, warn experts

Administering rabies vaccine at the wrong site can be fatal: Shoulders or thighs only, warn experts

Delhi HC allows Zydus to sell biosimilar of blockbuster anti-cancer drug Nivolumab

Delhi HC allows Zydus to sell biosimilar of blockbuster anti-cancer drug Nivolumab